commercialization

Iconovo is recruiting two new team members to increase the company’s commercialization and is now aiming for one to three new signed contracts per year. The aim is to reach small- and mid-sized innovation companies with Iconovo’s unique inhalers. Innovative customers have global ambitions, and therefore the inhalers must meet the regulatory requirements of the larger markets.

 

Communication and Marketing Manager

Eva Norell has been appointed Communication and Marketing Manager. Eva has broad experience in the pharmaceutical industry, and earlier in her career worked with sales in Sweden for both Pfizer and Sanofi. Most recently, she comes from a role as Marketing Manager at Gedea Biotech, where she was responsible for communication and marketing activities. Eva has broad experience of digital channels for both sales, marketing, and training initiatives from several different industries. At Iconovo, Eva will be responsible for all communication and marketing activities, including Inbound Marketing, a new focus area meant to highlight Iconovo’s expertise and offer, and generate new customer prospects.

 

Design Assurance Manager

Annika Antius has been appointed Design Assurance Manager. Annika has extensive experience in product development and quality assurance from the life science industry for both pharmaceuticals and medical devices. Most recently, she acted as QA R&D Project Manager at Baxter, where she was responsible for quality assurance of new and revised products. Annika started her career as an analytical chemist at AstraZeneca R&D Lund and has since worked as a project manager for business improvement projects at various life science companies. In recent years, she has specialized in quality assurance of medical device products and has, among other things, held the role of Quality Manager at Altran. Annika will be responsible for ensuring that the documentation of Iconovo’s inhalers and drug-device combinations meets regulatory requirements.

 

Important key competencies

“Today we have recruited two new important team members. Eva and Annika both have essential talents that Iconovo needs to raise the bar further and get one step closer to our goal of bringing products to market. The first drug registrations are not far away, and in the long term, our ambition is to ensure a steady stream of new product launches based on inhalers from Iconovo. With the new positions, we will be able to intensify our commercial approach and decisively work further to secure more customer contracts”, says Johan Wäborg, CEO of Iconovo.